课题基金 / 基金详情

Gut microbiota and inflammatory monocytes in colorectal cancer

Gut microbiota and inflammatory monocytes in colorectal cancer
结直肠癌中的肠道微生物群和炎症单核细胞
批准号:
8021447
负责人:
Wendy S. Garrett
金额:
$30.35万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-03-18 至 2016-02-29

项目摘要

项目成果

Wendy S. Garrett的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):结直肠癌(CRC)是美国癌症相关死亡的第二大原因,也是第三大常见癌症。炎症是致癌的关键因素,慢性炎症性疾病患者的癌症发病率增加。肿瘤微环境中的炎症可以促进癌细胞的增殖、存活和迁移。慢性炎症的结肠黏膜是肿瘤前病变;溃疡性结肠炎(UC)是CRC发展的最高危险因素之一。最近的数据表明,对共生肠道细菌的免疫反应可能影响结直肠癌和结肠炎相关结直肠癌(caCRC)的发展。然而,肠道微生物群如何形成导致慢性炎症和结直肠癌的粘膜免疫反应尚不清楚。重要的问题包括:(1)引起慢性炎症反应的肠道微生物群的特征是什么,驱动caccrc;(2)粘膜先天免疫亚群如何在不断发展的肿瘤微环境中发挥作用。该建议建立在我们最近对UC和caCRC自发小鼠模型的研究基础上,该模型是在缺乏适应性免疫的情况下由T-bet缺陷遗传驱动的,并且源于我们对引发结肠炎的微生物群落的初步数据。我们的具体目标是:1)确定粪便微生物群落成员在启动先天免疫驱动的炎症级联反应中所起的作用;2)在结肠炎、非典型增生和腺癌的转变过程中,研究单核细胞群及其募集、功能和对肠道微生物群的反应;3)对结肠炎、非典型增生和腺癌过渡期间的粪便微生物群落进行功能基因组分析。我们采用细胞生物学、免疫学和微生物学技术以及测序技术作为实验工具,并结合能够整合这些不同数据集的计算方法。通过分析肠道微生物群落和先天免疫亚群在驱动促肿瘤炎症中的功能,本研究将促进对宿主-微生物相互作用对肿瘤微环境进化的贡献的基本理解。由于我们使用的小鼠模型让人想起UC,并概括了人类ibd相关CRC的关键特征,我们预计我们的数据将适用于人类疾病,以及开发抗炎宿主和/或微生物导向的治疗方法,以防止癌症的发展和进展。
英文摘要
DESCRIPTION (provided by applicant): Colorectal cancer (CRC) is the second leading cause of cancer-related death and the third most common cancer in the US. Inflammation is a key contributor to carcinogenesis, and there is an increased incidence of cancer in patients with chronic inflammatory diseases. Inflammation in the tumor microenvironment can enhance cancer cell proliferation, survival, and migration. A chronically inflamed colonic mucosa is pro- neoplastic; and ulcerative colitis (UC) is one of the highest risk factors for the development of CRC. Recent data suggest that immune responses to commensal gut bacteria may influence the development of CRC and colitis-associated colorectal cancer (caCRC). However, how the gut microbiota shapes mucosal immune responses leading to chronic inflammation and CRC is not well understood. Important questions include: (1) what are the features of the gut microbiota that elicit chronic inflammatory responses that drive caCRC and (2) how do mucosal innate immune subsets function in the evolving tumor microenvironment. This proposal builds on our recent studies of a spontaneous mouse model of UC and caCRC that is driven genetically by T-bet deficiency in the absence of adaptive immunity, and stems from our preliminary data on the microbial communities that instigate colitis. Our specific aims are to: 1) define the role of fecal microbial community members in initiating the innate immune driven inflammatory cascades that drive caCRC; 2) characterize monocyte populations and their recruitment, function, and response to the intestinal microbiota across the colitis r dysplasia r adenocarcinoma transition; and 3) perform a functional genomic analysis of fecal microbial communities across the colitis r dysplasia r adenocarcinoma transition. We employ cell biology, immunology, and microbiology techniques and sequencing technology as experimental tools, in conjunction, with computational methodology capable of integrating these diverse data sets. By analyzing the function of intestinal microbial communities and innate immune subsets in driving pro-neoplastic inflammation, this proposal will advance basic understanding of the contribution of host-microbial interactions to the evolution of a tumor microenvironment. Since we utilize a mouse model that is reminiscent of UC and recapitulates key features of human IBD-associated CRC, we anticipate that our data will be applicable for human disease and for the development of anti-inflammatory host and/or microbe directed therapeutics that will prevent the development and progression of cancer. PUBLIC HEALTH RELEVANCE: Colorectal cancer is the second leading cause of cancer-related death and the third most common cancer in the US; and inflammation is a key contributor to carcinogenesis. Our proposal examines the role of inflammatory cells and gut bacteria in driving cancer in the colon.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Designer Probiotics for the treatment of intestinal infection and inflammation
  • 批准号:
    9356497
  • 项目类别:
  • 资助金额:
    $74.41万
  • 财政年份:
    2016
  • 负责人:
    Wendy S. Garrett
  • 依托单位:
Designer Probiotics for the treatment of intestinal infection and inflammation
  • 批准号:
    9769017
  • 项目类别:
  • 资助金额:
    $73.51万
  • 财政年份:
    2016
  • 负责人:
    Wendy S. Garrett
  • 依托单位:
Designer Probiotics for the treatment of intestinal infection and inflammation
  • 批准号:
    10004029
  • 项目类别:
  • 资助金额:
    $73.34万
  • 财政年份:
    2016
  • 负责人:
    Wendy S. Garrett
  • 依托单位:
Gut microbiota and inflammatory monocytes in colorectal cancer
  • 批准号:
    8816042
  • 项目类别:
  • 资助金额:
    $33.51万
  • 财政年份:
    2011
  • 负责人:
    Wendy S. Garrett
  • 依托单位:
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    雷芬芳
  • 依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    万荣
  • 依托单位: